Lek d.d.

Slovenialek.si

Its role Operator

project tracked
1
partner companies
2
news article
1

Lek d.d. is a Slovenian pharmaceutical company focused on the development, manufacturing, and commercialization of generic medicines and biosimilars. It operates as a key subsidiary within the Sandoz group, which forms the generics and biosimilars division of Novartis. The company maintains its headquarters in Ljubljana and runs several production facilities across Slovenia, including a major new biosimilars manufacturing site in Lendava.

Read more

Lek's core activities encompass research and development of pharmaceutical formulations, large-scale production of active ingredients and finished products, and global distribution. Its portfolio covers therapeutic areas such as oncology, immunology, cardiology, and central nervous system disorders. The firm emphasizes advanced biotechnological processes and has made substantial investments in biologics manufacturing capabilities.

Established in the mid-20th century, Lek has expanded through integration into the Novartis group while retaining its Slovenian operational base. It contributes significantly to the local economy as a major employer in the life sciences sector and holds a prominent position in the European generics and biosimilars market, supplying high-quality, cost-effective medicines internationally.

Also known as Lek Pharmaceuticals d.d..

The project Lek is involved in

chemXplore tracks 1 project involving Lek, of which one is active.

Sandoz biosimilar drug substance plant in Lendava, Slovenia
  1. Announced / Concept
  2. FEED / Pre-FID
  3. FID / Sanctioned
  4. Under Construction
  5. Commissioning & Start-up
Phase
Commissioning & Start-up
Where
Slovenia
Partners
Sandoz , Slovenian Government

Lek in chemical industry news

9 March 2023
Sandoz to Build New Biologics Plant in Slovenia

The $400M investment aims to boost biosimilar production, with operations starting in 2026. This supports the company's growth in biosimilars and antibiotics, enhancing access to critical medicines.

Where its projects are

active all projects